Author: OurCrowd

[Sight Diagnostics in Newswire] Sight Diagnostics® and Inter Medico announce the Health Canada approval of Sight OLO for point-of-care testing

Jan 11, 2022 | ,

Sight Diagnostics, the company delivering lab-grade Complete Blood Count (CBC) results in minutes, today announced it has received Health Canada approval to provide Sight OLO® analyzers for point-of-care settings. Through its distribution partner Inter Medico, Sight will bring the first and only 5-part differential CBC testing to emergency departments, hospitals, and other decentralized settings across Canada. Read...

Read More

[Flytrex in Spectrum News1] Drone delivery service brings food directly to backyards

Jan 10, 2022 |

Paul Rossi is the flight operation manager for Causey Aviation Unmanned and is working with Flytrex to deliver dinner to people’s backyards. Growing up, he said he always wanted to be a pilot. Now, he’s in charge of the entire drone pilot operation. The pilot program is just in Holly Springs now, but they hope to extend the opportunity to more pilots and customers. Read...

Read More

[Alpha Tau in PR Newswire] Alpha Tau announces results of first US clinical trial of Alpha DaRT™ in malignant skin & soft tissue cancers, showing complete response in all ten treated tumors at approximately 12 weeks and no product-related serious adverse events

Jan 10, 2022 |

Alpha Tau Medical Ltd. (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that all ten patients in its US multi-center pilot trial of the Alpha DaRT for malignant skin & soft tissue cancers have reached the secondary endpoint for measurement of tumor response. The study met its primary feasibility endpoint, as all patients had successful delivery of radiation by Alpha DaRT. At approximately 12 weeks, all ten tumors demonstrated a complete response, defined as disappearance of the treated tumor, as measured using RECIST v.1.1 criteria, and the safety profile has been consistent with the company’s other clinical trials, with no product-related serious adverse events observed to date. Read...

Read More